Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579969 | 0.86 | CYP11B1 (0.42) | CHEK1KDRCDK1CYP11B1CYP11B2 | |
| SCHEMBL23579966 | 0.84 | CHEK1 (0.38) | CYP1A2CHEK1SCN9AKDRCDK1 | |
| SCHEMBL23607245 | 0.81 | CYP17A1 (0.37) | CYP17A1CYP1A2 | |
| SCHEMBL29384197 | 0.80 | HDAC6 (0.47) | — | |
| SCHEMBL23580475 | 0.80 | HDAC6 (0.47) | — | |
| SCHEMBL23607242 | 0.76 | CNR2 (0.36) | CYP1A2CHEK1SCN9AKDRSYK | |
| SCHEMBL23579776 | 0.75 | CYP17A1 (0.42) | CYP17A1CYP1A2CHEK1SCN9AKDR | |
| SCHEMBL23579642 | 0.75 | CYP17A1 (0.49) | CYP17A1CYP1A2 | |
| SCHEMBL23579745 | 0.73 | CHEK1 (0.41) | CYP1A2CHEK1SCN9AKDRADORA2B | |
| SCHEMBL23580546 | 0.72 | KDR (0.39) | CYP1A2CHEK1SCN9AKDRADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | ONKURE, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| WO-2021133957-A1 | BENZIMIDAZOLE COMPOUNDS AS HDAC6 INHIBITORS | ONKURE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339150-B2 | Benzimidazole compounds as HDAC6 inhibitors | HDAC6, HDAC1, HDAC11 | CYP17A1 2453/4885CYP1A2 1128/4885CHEK1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.